These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35719134)

  • 1. Digital biomarkers and sex impacts in Alzheimer's disease management - potential utility for innovative 3P medicine approach.
    Harms RL; Ferrari A; Meier IB; Martinkova J; Santus E; Marino N; Cirillo D; Mellino S; Catuara Solarz S; Tarnanas I; Szoeke C; Hort J; Valencia A; Ferretti MT; Seixas A; Santuccione Chadha A
    EPMA J; 2022 Jun; 13(2):299-313. PubMed ID: 35719134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects.
    Moradi E; Pepe A; Gaser C; Huttunen H; Tohka J;
    Neuroimage; 2015 Jan; 104():398-412. PubMed ID: 25312773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction and Classification of Alzheimer's Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers.
    Gupta Y; Lama RK; Kwon GR;
    Front Comput Neurosci; 2019; 13():72. PubMed ID: 31680923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review.
    Piau A; Wild K; Mattek N; Kaye J
    J Med Internet Res; 2019 Aug; 21(8):e12785. PubMed ID: 31471958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
    Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood transcriptome profiling as potential biomarkers of suboptimal health status: potential utility of novel biomarkers for predictive, preventive, and personalized medicine strategy.
    Wang H; Tian Q; Zhang J; Liu H; Zhang J; Cao W; Zhang X; Li X; Wu L; Song M; Kong Y; Wang W; Wang Y
    EPMA J; 2021 Jun; 12(2):103-115. PubMed ID: 34194583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study.
    Meier IB; Buegler M; Harms R; Seixas A; Çöltekin A; Tarnanas I
    NPJ Digit Med; 2021 Jun; 4(1):101. PubMed ID: 34168269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's Disease: Epidemiology and Clinical Progression.
    Tahami Monfared AA; Byrnes MJ; White LA; Zhang Q
    Neurol Ther; 2022 Jun; 11(2):553-569. PubMed ID: 35286590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study.
    Song R; Wu X; Liu H; Guo D; Tang L; Zhang W; Feng J; Li C
    Korean J Radiol; 2022 Jan; 23(1):89-100. PubMed ID: 34983097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?
    Tarnanas I; Tsolaki A; Wiederhold M; Wiederhold B; Tsolaki M
    Alzheimers Dement (Amst); 2015 Dec; 1(4):521-32. PubMed ID: 27239530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease.
    Tieu MV; Choi SH; Le HTN; Cho S
    Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study.
    Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J;
    Front Neurol; 2021; 12():695696. PubMed ID: 34557143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.